Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 222

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 222
---
Company sold 12,246,318 shares of Common Stock pursuant to the New Keystone Purchase agreement for gross proceeds of $1,540,290.

33

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s
Discussion and Analysis of Financial Condition and Results of Operations provides information that CERo Therapeutics Holdings, Inc. (“the
Company”) management believes is relevant to an assessment and understanding of its results of operations and financial condition.
The discussion should be read together with (i) the Company’s unaudited condensed consolidated financial statements and related
notes that are presented above and (ii) the Company’s audited consolidated financial statements and related notes and management’s
discussion and analysis of financial condition and results of operations included in the Company’s Annual Report on Form 10-K for
the year ended December 31, 2024 filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2025. This Management’s
Discussion and Analysis of Financial Condition and Results of Operations may contain forward-looking statements based upon current expectations
that involve risks and uncertainties. Actual results may differ materially from those anticipated in these forward-looking statements
resulting from various factors. Please see “Cautionary Note Regarding Forward Looking Statements” and “Risk Factors”
in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the subsequent Quarterly Report on Form 10-Q
as filed with the SEC. Unless the context otherwise requires, references in this section to “Predecessor” is intended to mean
the business and operations of CERo Therapeutics, Inc. prior to the Merger.

Overview

CERo Therapeutics, Inc. (the
“Predecessor”) was incorporated in Delaware on September 23, 2016, and is based in South San Francisco, California. Predecessor
was focused on developing its therapeutic platform to genetically engineer human immune cells to fight cancer and did not begin clinical
development or product commercialization. The Company’s efforts will focus on continued product development, including clinical
development, to support regulatory approval to commercialize and subsequent product commercialization.

On June 4, 2023, Predecessor
entered into a Business Combination Agreement (as amended by that certain Amendment No. 1 to the Business Combination Agreement, dated
as of February 5, 2024 and Amendment No. 2 to the Business